• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LENSAR Inc.

    3/5/24 4:10:25 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care
    Get the next $LNSR alert in real time by email
    S-8 1 lnsr-s8-2024.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on March 5, 2024

    Registration No. 333-

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    LENSAR, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

     

    32-0125724

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    2800 Discovery Drive,

    Orlando, Florida

    32826

    (Address of Principal Executive Offices)

    (Zip Code)

     

    2024 Employment Inducement Incentive Award Plan

    2020 Incentive Award Plan

    2020 Employee Stock Purchase Plan

    (Full title of the plans)

    Nicholas T. Curtis

    Chief Executive Officer

    LENSAR, Inc.

    2800 Discovery Drive,

    Orlando, FL 32826

    (888) 536-7271

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

    B. Shayne Kennedy

    Drew Capurro

    Latham & Watkins LLP

    650 Town Center Drive, 20th Floor

    Costa Mesa, CA 92626

    (714) 540-1235

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

     

    Accelerated filer

    ☐

    Non-accelerated filer

    ☒

     

    Smaller reporting company

    ☒

     

     

     

    Emerging growth company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     


     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (the “Registration Statement”) is being filed with the Securities and Exchange Commission (the “Commission”) for the purpose of registering (a) 100,000 shares of common stock, par value $0.01 per share (the “Common Stock”), of LENSAR, Inc. (the “Registrant”) reserved for issuance under the Registrant’s 2024 Employment Inducement Incentive Award Plan, to be granted to certain eligible individuals as an inducement material to their entering into employment with the Registrant, and (b) an additional 679,609 shares of Common Stock issuable under the following employee benefit plans for which registration statements of the Registrant on Form S-8 (File Nos. 333-249323, 333-263276 and 333-270703) are effective: (i) the 2020 Incentive Award Plan, pursuant to the automatic annual increase provision therein, which added 566,341 shares of Common Stock, and (ii) the 2020 Employee Stock Purchase Plan, pursuant to the automatic annual increase provision therein, which added 113,268 shares of Common Stock.

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Registration Statement (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Commission.

     

     


     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents, which have been filed with the Commission by the Registrant pursuant to the Securities Act of 1933, as amended (the “Securities Act”), and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as applicable, are hereby incorporated by reference in, and shall be deemed to be a part of, this Registration Statement:

    (a)
    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023;
    (b)
    The Registrant’s Current Reports on Form 8-K filed with the Commission on February 6, 2024 and February 26, 2024; and
    (c)
    The Registrant’s Registration Statement on Form 10, initially filed with the Commission on August 25, 2020, as amended on September 14, 2020, pursuant to Section 12(b) of the Securities Act, as updated by “Description of Registered Securities” filed as Exhibit 4.2 to the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this Registration Statement (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 and/or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission) and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all such securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of filing of such documents.

    Any statement contained in this Registration Statement, in an amendment hereto or in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed amendment to this Registration Statement or in any document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement, except as to such specific section of such statements as set forth therein.

    Item 4. Description of Securities.

    Not applicable.

    Item 5. Interests of Named Experts and Counsel.

    Not applicable.

    Item 6. Indemnification of Directors and Officers.

    Section 102 of the General Corporation Law of the State of Delaware permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s certificate of incorporation provides that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the General Corporation Law of the State of Delaware prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

     


     

    Section 145 of the General Corporation Law of the State of Delaware provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    The Registrant’s certificate of incorporation provides that the Registrant will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of it) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. The Registrant’s certificate of incorporation provides that the Registrant will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of the Registrant to procure a judgment in the Registrant’s favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at the Registrant’s request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by the Registrant against all expenses (including attorneys’ fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances.

    The Registrant has entered into indemnification agreements with each of the Registrant’s directors and officers. These indemnification agreements may require the Registrant, among other things, to indemnify its directors and officers for some expenses, including attorneys’ fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of the Registrant’s directors or officers, or any other company or enterprise to which the person provides services at the Registrant’s request.

    The Registrant maintains a general liability insurance policy that covers certain liabilities of directors and officers of the Registrant’s corporation arising out of claims based on acts or omissions in their capacities as directors or officers.

    Item 7. Exemption from Registration Claimed.

    Not applicable.

     


     

    Item 8. Exhibits.

    Exhibit

     

     

     

     

     

    Incorporated by Reference

     

    Filed

    Number

     

     

    Exhibit Description

     

    Form

     

    File Number

    Filing Date

     

    Exhibit

     

    Herewith

     

     

     

     

     

     

     

     

    3.1

     

     

    Amended and Restated Certificate of Incorporation of LENSAR, Inc.

     

    8-K

     

    001-39473

    10/02/2020

     

    3.1

     

     

     

     

     

     

     

     

     

     

    3.2

     

     

    Second Amended and Restated Bylaws of LENSAR, Inc.

     

    10-K

     

    001-39473

    03/12/2021

     

    3.2

     

     

     

     

     

    3.3

     

     

    Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock filed May 18, 2023

     

    8-K

     

    001-39473

    05/18/2023

     

    3.1

     

     

     

     

     

     

    4.1

     

     

    Form of Certificate of Common Stock

     

    10/A

     

    001-39473

    09/14/2020

     

    4.1

     

     

     

     

    5.1

     

     

    Opinion of Latham & Watkins LLP

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

    23.1

     

     

    Consent of Independent Registered Public Accounting Firm (PricewaterhouseCoopers LLP)

     

     

     

     

     

     

     

     

    X

     

     

    23.2

     

     

    Consent of Latham & Watkins LLP (included in Exhibit 5.1)

     

     

     

     

     

     

     

     

    X

     

     

    24.1

     

     

    Power of Attorney (included on signature page)

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

    99.1

     

     

    2020 Incentive Award Plan

     

    S-8

     

    001-39473

    10/05/2020

     

    10.1

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.2

     

     

    Form of Restricted Stock Award Agreement pursuant to 2020 Incentive Award Plan

     

    S-8

     

    001-39473

    10/05/2020

     

    10.2

     

     

     

     

     

     

     

     

     

     

    99.3

     

     

    Form of Stock Option Agreement pursuant to 2020 Incentive Award Plan

     

    10-K

     

    001-39473

    03/03/2022

     

    10.5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.4

     

     

    Form of Restricted Stock Unit Agreement pursuant to 2020 Incentive Award Plan

     

    10-K

     

    001-39473

    03/03/2022

     

    10.6

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.5

     

     

    2020 Employee Stock Purchase Plan

     

    10/A

     

    001-39473

    09/14/2020

     

    10.5

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.6

     

     

    2024 Employment Inducement Incentive Award Plan

     

    8-K

     

    001-39473

    02/26/2024

     

    10.1

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.7

     

     

    Form of Stock Option Grant Notice pursuant to 2024 Employment Inducement Incentive Award Plan

     

    8-K

     

    001-39473

    02/26/2024

     

    10.2

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    99.8

     

     

    Form of Restricted Stock Unit Grant Notice pursuant to 2024 Employment Inducement Incentive Award Plan

     

    8-K

     

    001-39473

    02/26/2024

     

    10.3

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    107.1

     

     

    Filing Fee Table

     

     

     

     

     

     

     

     

    X

     

     


     

    Item 9. Undertakings.

    (a)
    The undersigned Registrant hereby undertakes:
    1.
    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
    i.
    To include any prospectus required by Section 10(a)(3) of the Securities Act;
    ii.
    To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Filing Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective Registration Statement; and
    iii.
    To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

    provided, however, that Paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

    2.
    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    3.
    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
    (b)
    The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
    (c)
    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Orlando, State of Florida, on March 5, 2024.

     

     

     

    LENSAR, INC.

     

     

    By

     

    /s/ Nicholas T. Curtis

     

     

    Nicholas T. Curtis

     

     

    Chief Executive Officer

    SIGNATURES AND POWER OF ATTORNEY

    We, the undersigned officers and directors of LENSAR, Inc., hereby severally constitute and appoint Nicholas T. Curtis and Thomas R. Staab, II, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign this registration statement and any and all amendments (including post-effective amendments) to this registration statement and all documents relating thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities held on the dates indicated.

     

     

    Name

    Title

    Date

    /s/ Nicholas T. Curtis

    Chief Executive Officer and Director

    (principal executive officer)

    March 5, 2024

    Nicholas T. Curtis

     

     

     

     

    /s/ Thomas R. Staab, II

    Chief Financial Officer

    (principal financial officer)

    March 5, 2024

    Thomas R. Staab, II

     

     

     

     

     

     

     

    /s/ Kendra W. Wong

    Principal Accounting Officer

    (principal accounting officer)

    March 5, 2024

    Kendra W. Wong

     

     

     

     

    /s/ William J. Link, Ph.D.

    Chairperson of the Board of Directors

    March 5, 2024

    William J. Link, Ph.D.

     

     

     

     

    /s/ Thomas B. Ellis

     

    Director

     

    March 5, 2024

    Thomas B. Ellis

     

     

     

     

     

     

     

     

     

    /s/ Todd B. Hammer

     

    Director

     

    March 5, 2024

    Todd B. Hammer

     

     

     

     

     

     

     

     

     

     


     

    /s/ Richard L. Lindstrom, M.D.

    Director

    March 5, 2024

    Richard L. Lindstrom, M.D.

     

     

     

     

    /s/ Elizabeth G. O’Farrell

    Director

    March 5, 2024

    Elizabeth G. O’Farrell

     

     

     

     

    /s/ Aimee S. Weisner

    Director

    March 5, 2024

    Aimee S. Weisner

     

     

     

     

    /s/ Gary M. Winer

    Director

    March 5, 2024

    Gary M. Winer

     

     

     


    Get the next $LNSR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNSR

    DatePrice TargetRatingAnalyst
    11/22/2021$15.00Buy
    BTIG
    More analyst ratings

    $LNSR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    ORLANDO, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company") today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ("RSUs"). The RSUs were granted as of September 2, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the

    9/2/25 4:01:44 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    SEC Filings

    View All

    LENSAR Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - LENSAR, Inc. (0001320350) (Filer)

    12/19/25 4:01:27 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by LENSAR Inc.

    SCHEDULE 13G - LENSAR, Inc. (0001320350) (Subject)

    11/13/25 12:03:17 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LENSAR Inc.

    10-Q - LENSAR, Inc. (0001320350) (Filer)

    11/6/25 4:01:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Winer Gary M bought $3,082 worth of shares (685 units at $4.50), increasing direct ownership by 0.85% to 80,840 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    9/6/24 9:00:13 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $10,373 worth of shares (2,302 units at $4.51), increasing direct ownership by 3% to 80,155 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/29/24 6:05:46 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Director Winer Gary M bought $2,185 worth of shares (502 units at $4.35), increasing direct ownership by 0.65% to 77,853 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    8/23/24 6:52:16 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Staab Thomas R Ii covered exercise/tax liability with 1,826 shares, decreasing direct ownership by 1% to 171,535 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:07 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Curtis Nicholas T disposed of 0 shares (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:11 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Connaughton Alan B. covered exercise/tax liability with 2,262 shares, decreasing direct ownership by 0.63% to 359,461 units (SEC Form 4)

    4 - LENSAR, Inc. (0001320350) (Issuer)

    1/13/26 4:30:06 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG initiated coverage on LENSAR with a new price target

    BTIG initiated coverage of LENSAR with a rating of Buy and set a new price target of $15.00

    11/22/21 6:09:40 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    3/2/21 8:10:50 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SVB Leerink initiated coverage on LENSAR with a new price target

    SVB Leerink initiated coverage of LENSAR with a rating of Outperform and set a new price target of $20.00

    2/24/21 6:12:20 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Leadership Updates

    Live Leadership Updates

    View All

    SpyGlass Pharma Appoints Elizabeth O'Farrell to its Board of Directors

      ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O'Farrell to its Board of Directors as an Independent Director and Chair of the Audit Committee, effective immediately. Ms. O'Farrell brings over three decades of industry experience, spanning strategic planning, financial optimization, regulatory compliance and management. "Liz's established track record in large, commercial healthcare organizations with deep experience in global finance and operations will be instrumental as we continue to advance our SpyGlass Drug Delivery Platform into two pivotal Phase 3 tria

    8/19/25 8:00:13 AM ET
    $GERN
    $GMAB
    $LNSR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $LNSR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LENSAR Inc.

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    11/14/24 4:05:15 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/14/24 4:05:39 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LENSAR Inc. (Amendment)

    SC 13G/A - LENSAR, Inc. (0001320350) (Subject)

    2/13/24 4:30:02 PM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    $LNSR
    Financials

    Live finance-specific insights

    View All

    LENSAR Reports Second Quarter 2025 Results and Provides Business Update

    18 ALLY Robotic Cataract Laser Systems™ ("ALLY Systems") placed in 2Q 2025 with an additional backlog of 18 ALLY Systems pending installation as of June 30, 2025 ALLY installed base grew 107% and total installed base grew 23% over 2Q 2024 Worldwide procedure volumes increased 23% over 2Q 2024 ORLANDO, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended June 30, 2025 and provided an update on key operational initiatives. "Our second quarter results reflect the continued, strong

    8/7/25 7:00:16 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports First Quarter 2025 Results and Provides Business Update

             14 ALLY Robotic Laser Cataract Systems™ ("ALLY Systems") placed in 1Q 2025 with an additional backlog of 24 systems pending installation as of March 31, 2025 34% Revenue growth over the first quarter 2024 and 22% Recurring revenue growth in the trailing twelve months Worldwide procedure volumes increased 33% over the first quarter of 2024 ORLANDO, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financial results for the quarter ended March 31, 2025 and provided an update on key operational initiatives. "W

    5/8/25 7:00:42 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care

    LENSAR Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

    31 ALLY Robotic Cataract Laser Systems™ placed in Q4 2024, representing an 86% increase in ALLY placements in full year 2024 over 2023; Company's total installed systems increased to approximately 385 as of December 31, 2024, representing a 26% increase over 2023 Fourth quarter 2024 revenue increased 38% over fourth quarter 2023; Full-year revenue increased 27% over 2023 Recurring revenue exceeds $40 million for the full year; increased 23% over 2023 ORLANDO, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, today announced financia

    2/27/25 7:00:11 AM ET
    $LNSR
    Medical/Dental Instruments
    Health Care